Back to top

Leerink says removal of C-peptide requirement would benefit pump market, Tandem

Leerink analyst Mike Kratky notes that a new sub-analysis showing similar clinical benefits of AID in T2 patients regardless of their C-peptide lev...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Beta Bionics, Inc. (BBNX)

Medtronic PLC (MDT)

Tandem Diabetes Care, Inc. (TNDM)